Leukemia test kit Xpert®

for BCR-ABL mutationslaboratoryreal-time

The ongoing presence of the Ph chromosome in ALL patients after consolidation therapy is a significant predictor of relapse, and monitoring is recommended. Established international organizations recommend definitive timepoints for monitoring BCR-ABL p190 in ALL and CML patients.7-10 Unlike the BCR-ABL World Health Organization international standard (WHO IS) for the p210 transcript, currently, there are no international standards that can be used to standardize the p190 fusion transcript, posing a challenge for a quantitative assay monitoring p190 transcript level. Current testing options for BCR-ABL p190 monitoring for both CML and ALL patients are not only cumbersome, but can be expensive and time consuming for the lab to implement because: Available testing methods can be complex and create inefficient laboratory workflows. No international scale has been established for p190 monitoring, so laboratories are dependent on ratios and must run laborious standard curves. The Solution Xpert BCR-ABL Ultra p190 is an automated test for quantifying the amount of BCR-ABL p190 transcript as a ratio of BCR-ABL p190/ABL with high sensitivity. Based on the innovative GeneXpert® technology, Xpert BCR-ABL Ultra p190 automates the testing procedure, including RNA isolation, reverse transcription, and fully nested real-time PCR of BCR-ABL target gene and ABL reference gene in one automated cartridge. Leveraging Cepheid’s lab in a cartridge™ technology, the Xpert BCR-ABL p190 test decreases workflow complexity and hands-on time by automating the entire testing process, delivering faster results.